Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Innovative Global R&D Collaboration Between Insilico Medicine and Eli Lilly to Advance Drug Discovery Insilico Medicine and Eli Lilly have entered a groundbreaking collaboration leveraging artificial intelligence for drug discovery in various therapeutic areas.

Innovative Global R&D Collaboration Between Insilico Medicine and Eli Lilly to Advance Drug Discovery #USA #Cambridge #Insilico_Medicine #AI_Drug_Discovery #Lilly

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Insilico Medicine and Tenacia Biotechnology Collaborate for CNS Innovations Worth Up to $94.75 Million Insilico Medicine and Tenacia Biotechnology have expanded their partnership to enhance AI-driven CNS therapies, with potential deal value maxing at $94.75 million.

Insilico Medicine and Tenacia Biotechnology Collaborate for CNS Innovations Worth Up to $94.75 Million #United_States #Cambridge #Insilico_Medicine #CNS_therapies #Tenacia_Biotechnology

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Insilico Medicine's PandaClaw Revolutionizes Therapeutic Discovery with AI Technologies Insilico Medicine introduces PandaClaw, an advanced AI tool that simplifies therapeutic discovery for biologists by automating complex analyses and offering real-time insights.

Insilico Medicine's PandaClaw Revolutionizes Therapeutic Discovery with AI Technologies #United_States #Cambridge #Insilico_Medicine #AI_Drug_Discovery #PandaClaw

Thiard News@F4F

@newsen.bsky.social

1 month ago

Insilico and TaiGen Celebrate Clinical Milestone for CKD Anemia Treatment ISM4808 Insilico Medicine and TaiGen Biotechnology announce the successful completion of first human enrollment for ISM4808, a new CKD anemia treatment.

Insilico and TaiGen Celebrate Clinical Milestone for CKD Anemia Treatment ISM4808 #None #Insilico_Medicine #CKD_Anemia #TaiGen_Biotechnology

Thiard News@F4F

@newsen.bsky.social

1 month ago

Innovative Partnership Between Insilico Medicine and Liquid AI Enhances Drug Discovery with Lightweight Models Insilico Medicine and Liquid AI have teamed up to develop innovative lightweight models for drug discovery, aiming to streamline pharmaceutical research while maintaining data security.

Innovative Partnership Between Insilico Medicine and Liquid AI Enhances Drug Discovery with Lightweight Models #USA #Cambridge #Drug_Discovery #Insilico_Medicine #Liquid_AI

Thiard News@F4F

@newsen.bsky.social

2 months ago

Accelerating Drug Discovery: The Innovative Collaborations Between Insilico Medicine and CMS Insilico Medicine partners with CMS to leverage AI-driven drug discovery for central nervous system and autoimmune diseases, enhancing treatment options.

Accelerating Drug Discovery: The Innovative Collaborations Between Insilico Medicine and CMS #China #Cambridge #Insilico_Medicine #CMS #AI_Drug_Discovery

Thiard News@F4F

@newsen.bsky.social

2 months ago

Insilico Medicine Appoints Dr. Halle Zhang to Spearhead Oncology Development Insilico Medicine has appointed Dr. Halle Zhang as Vice President of Clinical Development for Oncology, leading innovative cancer therapies. Her expertise will help accelerate clinical strategies.

Insilico Medicine Appoints Dr. Halle Zhang to Spearhead Oncology Development #United_States #Cambridge #oncology #Insilico_Medicine #Halle_Zhang

Thiard News@F4F

@newsen.bsky.social

2 months ago

Insilico Medicine Advances ISM5059 as a Novel NLRP3 Inhibitor for Systemic Inflammation Treatment Insilico Medicine has nominated ISM5059, a peripheral NLRP3 inhibitor, as a preclinical candidate for treating systemic inflammation, showcasing AI-driven drug discovery's potential.

Insilico Medicine Advances ISM5059 as a Novel NLRP3 Inhibitor for Systemic Inflammation Treatment #Hong_Kong #Insilico_Medicine #NLRP3 #ISM5059

Thiard News@F4F

@newsen.bsky.social

2 months ago

Insilico Medicine Unveils ISM0676: A Potential Game-Changer for Obesity Treatment with Significant Body Weight Loss Insilico Medicine has introduced ISM0676, an innovative GIPR antagonist, showing impressive results in body weight reduction and metabolic stability for obesity and related diseases.

Insilico Medicine Unveils ISM0676: A Potential Game-Changer for Obesity Treatment with Significant Body Weight Loss #Cambridge #無し #Insilico_Medicine #GIPR #ISM0676

Thiard News@F4F

@newsen.bsky.social

2 months ago

Insilico Medicine's ISM8969 Achieves IND Approval from FDA, Pioneering AI-Led Drug Development Insilico Medicine's ISM8969 secures IND approval from the FDA, paving the way for clinical trials, showcasing AI's potential in drug development.

Insilico Medicine's ISM8969 Achieves IND Approval from FDA, Pioneering AI-Led Drug Development #United_States #Cambridge #Insilico_Medicine #NLRP3_Inhibitor #ISM8969

Thiard News@F4F

@newsen.bsky.social

2 months ago

Insilico Medicine Launches the Science MMAI Gym: A New Era in Drug Discovery Technologies Insilico Medicine introduces the Science MMAI Gym to enhance AI-driven drug discovery, improving LLM performance significantly for pharmaceutical applications.

Insilico Medicine Launches the Science MMAI Gym: A New Era in Drug Discovery Technologies #United_States #Cambridge #Drug_Discovery #Insilico_Medicine #Science_MMAI_Gym

Thiard News@F4F

@newsen.bsky.social

2 months ago

Insilico Medicine and Hygtia Therapeutics Team Up on Groundbreaking NLRP3 Inhibitor for CNS Diseases Insilico Medicine and Hygtia Therapeutics have announced a strategic collaboration to co-develop ISM8969, an innovative NLRP3 inhibitor targeting CNS disorders, highlighting a significant advancement in therapeutic options.

Insilico Medicine and Hygtia Therapeutics Team Up on Groundbreaking NLRP3 Inhibitor for CNS Diseases #None #Insilico_Medicine #Hygtia_Therapeutics #NLRP3_Inhibitor

Thiard News@F4F

@newsen.bsky.social

3 months ago

Insilico Medicine Advances Garutadustat in Phase II Trial for IBD Treatment Insilico Medicine announces successful first dose in a Phase II trial for Garutadustat, aiming to treat Inflammatory Bowel Disease (IBD) efficiently.

Insilico Medicine Advances Garutadustat in Phase II Trial for IBD Treatment #United_States #Bethesda #IBD_treatment #Insilico_Medicine #Garutadustat

Thiard News@F4F

@newsen.bsky.social

3 months ago

Insilico Medicine Engages in $888 Million Partnership with Servier for Innovative Cancer Therapies Insilico Medicine has formed an $888 million R&D collaboration with Servier, aiming to leverage AI technology for oncology drug development. This partnership will enhance drug discovery processes significantly.

Insilico Medicine Engages in $888 Million Partnership with Servier for Innovative Cancer Therapies #USA #Cambridge #oncology #Insilico_Medicine #Servier

Thiard News@F4F

@newsen.bsky.social

3 months ago

Insilico Medicine Achieves Milestone IPO at Hong Kong Stock Exchange, Transforming Drug Discovery Landscape Insilico Medicine, backed by Qiming Venture Partners, makes a significant IPO debut on Hong Kong Stock Exchange, setting new benchmarks in biotech.

Insilico Medicine Achieves Milestone IPO at Hong Kong Stock Exchange, Transforming Drug Discovery Landscape #China #Shanghai #Insilico_Medicine #AI_Drug_Discovery #Qiming_Venture_Partners

Thiard News@F4F

@newsen.bsky.social

3 months ago

Insilico Medicine's Successful Hong Kong Stock Exchange Listing Marks Milestone for AI-Driven Drug Discovery Insilico Medicine has made headlines with its successful IPO on the Hong Kong Stock Exchange, driving innovation in AI-based drug discovery and expanding its market presence.

Insilico Medicine's Successful Hong Kong Stock Exchange Listing Marks Milestone for AI-Driven Drug Discovery #China #Shanghai #Insilico_Medicine #AI_Drug_Discovery #Qiming_Venture_Partners

Thiard News@F4F

@newsen.bsky.social

3 months ago

Insilico Medicine Launches Groundbreaking Biotech IPO on Hong Kong Stock Exchange in 2025 Insilico Medicine emerges as a leader in AI-driven drug discovery with a successful IPO on the Hong Kong Stock Exchange, raising HKD 2.277 billion.

Insilico Medicine Launches Groundbreaking Biotech IPO on Hong Kong Stock Exchange in 2025 #None #Hong_Kong #Insilico_Medicine #AI_Drug_Discovery #Hong_Kong_IPO

Thiard News@F4F

@newsen.bsky.social

4 months ago

Insilico Medicine and TaiGen Partner to Combat Chronic Kidney Disease Anemia with Innovative AI Therapies Insilico Medicine and TaiGen join forces to advance ISM4808, an AI-developed inhibitor for treating anemia in chronic kidney disease, aiming to enhance patient care.

Insilico Medicine and TaiGen Partner to Combat Chronic Kidney Disease Anemia with Innovative AI Therapies #None #Insilico_Medicine #TaiGen #CKD_Anemia

Thiard News@F4F

@newsen.bsky.social

5 months ago

Insilico and Lilly Collaborate on Innovative AI-Driven Drug Discovery Partnership Insilico Medicine has partnered with Eli Lilly to enhance AI-driven drug discovery, combining expertise in innovative therapies that tackle unmet medical needs.

Insilico and Lilly Collaborate on Innovative AI-Driven Drug Discovery Partnership #United_States #Cambridge #Eli_Lilly #Insilico_Medicine #AI_Drug_Discovery

Thiard News@F4F

@newsen.bsky.social

10 months ago

Insilico Medicine's Groundbreaking Publication on Rentosertib and AI-Driven Drug Development Insilico Medicine has made significant strides in drug development with Rentosertib for IPF, utilizing innovative AI techniques. Promising results were published.

Insilico Medicine's Groundbreaking Publication on Rentosertib and AI-Driven Drug Development #United_States #Cambridge #Insilico_Medicine #AI_Drug_Discovery #Rentosertib

Thiard News@F4F

@newsen.bsky.social

1 year ago

Strategic Alliance Formed Between Harbour BioMed and Insilico Medicine to Propel AI-Driven Antibody Innovations Harbour BioMed and Insilico Medicine have joined forces to enhance antibody discovery using cutting-edge AI technology, aiming for groundbreaking medical advancements.

Strategic Alliance Formed Between Harbour BioMed and Insilico Medicine to Propel AI-Driven Antibody Innovations #None #Insilico_Medicine #Harbour_BioMed #Antibody_Discovery

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group Partners with Insilico Medicine for Innovative Oncology Solution Menarini and Insilico Medicine have finalized a second licensing agreement focusing on an AI-discovered oncology treatment, addressing significant unmet medical needs.

Menarini Group Partners with Insilico Medicine for Innovative Oncology Solution #USA #Florence #Menarini_Group #Insilico_Medicine #Stemline_Therapeutics

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini and Insilico Medicine Collaborate on New Oncology Drug Development Using AI Technology Menarini Group announces a second global license agreement with Insilico Medicine for an AI-developed oncology drug targeting unmet needs, enhancing cancer treatments.

Menarini and Insilico Medicine Collaborate on New Oncology Drug Development Using AI Technology #Italy #oncology #Florence #Menarini_Group #Insilico_Medicine

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini and Insilico Medicine Collaborate on AI-Driven Preclinical Oncology Asset Menarini Group and Insilico Medicine have executed a global license agreement for an AI-discovered preclinical oncology asset, aiming to tackle significant unmet medical needs.

Menarini and Insilico Medicine Collaborate on AI-Driven Preclinical Oncology Asset #Italy #oncology #Florence #Menarini_Group #Insilico_Medicine

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group Expands Oncology Portfolio with New AI-Driven Licensing Partnership Menarini Group has secured a second exclusive global licensing agreement with Insilico Medicine for a promising preclinical oncology asset, marking a significant development in cancer treatment.

Menarini Group Expands Oncology Portfolio with New AI-Driven Licensing Partnership #USA #oncology #Menarini_Group #Insilico_Medicine #Florence,_Italy;_Cambridge,_Massachusetts

Thiard News@F4F

@newsen.bsky.social

1 year ago

Menarini Group and Insilico Medicine Expand Collaboration with New AI-Driven Oncology License Menarini Group has secured a second exclusive global license from Insilico Medicine for an AI-discovered preclinical oncology asset. This deal has the potential to address urgent medical needs in cancer treatment.

Menarini Group and Insilico Medicine Expand Collaboration with New AI-Driven Oncology License #Italy #Florence #Menarini_Group #Insilico_Medicine #Oncology_Treatment

Thiard News@F4F

@newsen.bsky.social

1 year ago

Insilico Medicine Reports Successful Phase 1 Trials of ISM5411 for IBD Insilico Medicine announces positive Phase I trial results for ISM5411, a new AI-designed drug for treating inflammatory bowel disease, showing safety and efficacy.

Insilico Medicine Reports Successful Phase 1 Trials of ISM5411 for IBD #United_States #Cambridge #Inflammatory_Bowel_Disease #Insilico_Medicine #ISM5411

Thiard News@F4F

@newsen.bsky.social

1 year ago

Innovative Generative Chemistry Drives Gut-Restricted PHD Inhibitor Development for IBD Treatments Insilico Medicine leverages generative chemistry to develop gut-restricted PHD inhibitors, offering new hope for treating inflammatory bowel disease.

Innovative Generative Chemistry Drives Gut-Restricted PHD Inhibitor Development for IBD Treatments #United_States #Cambridge #IBD_Treatments #Insilico_Medicine #PHD_Inhibitors